Galderma Pharma S.A. Initiates Clinical Development of Novel Muscle Relaxant

Published: Jun 05, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma today announced that it has initiated clinical development of a novel muscle relaxant, based on an advanced formulation of botulinum toxin, with the first cohort of patients already treated in the initial clinical study. “Muscle relaxants are a key medical solution aesthetic physicians can use to create balanced and optimal results for their patients. We aim to strengthen our portfolio with a new and proprietary muscle relaxant in territories where Galderma does not have access to Azzalure/Dysport, such as North America” commented Humberto C. Antunes, President and CEO of Galderma. “We look forward to rapidly advancing this innovative product in countries where we do not currently promote Azzalure or Dysport in aesthetics.”

Help employers find you! Check out all the jobs and post your resume.

Back to news